Interpreting 7-Year Valve Durability in PARTNER 3—Reply - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Reply: Interpreting Seven-Year Valve Durability Findings From PARTNER 3

  • By

  • Philippe Pibarot

  • Julien Ternacle

  • Rebecca Hahn

  • November 1, 2026

Share

Clinical Scorecard: Reply: Interpreting Seven-Year Valve Durability Findings From PARTNER 3

At a Glance

CategoryDetail
ConditionLong-term durability of transcatheter and surgical bioprosthetic aortic valves
Key MechanismsBioprosthetic valve failure (BVF) includes reintervention, valve-related death, and irreversible severe bioprosthetic valve dysfunction; structural valve deterioration (SVD) is a cause of BVF.
Target PopulationPatients with aortic stenosis undergoing TAVR or surgical valve replacement, with PARTNER 3 enrolling low-risk patients.
Care SettingRandomized-trial comparison of TAVR and surgical aortic valve replacement, interpreted in the context of contemporary valve selection and lifetime management.

Key Highlights

  • Sensitivity analyses excluding Trifecta and Mitroflow valves found comparable all-cause BVF rates for TAVR and surgery (6.9% vs 5.4%; P = .42).
  • SVD-attributable BVF rates were also comparable between TAVR and surgery (3.9% vs 3.4%; P = .69) in those sensitivity analyses.
  • The authors describe all-cause BVF as a more comprehensive durability end point than reintervention alone because it also includes valve-related death and irreversible severe valve dysfunction.
  • Mechanical valve replacement was largely infeasible in PARTNER 3: no participants were younger than 50 years, and 9.5% were aged 50 to 65 years.
  • The possibility that Resilia tissue could improve TAVR durability relative to surgery is described as hypothetical.

Guideline-Based Recommendations

Diagnosis

    Management

    • The authors state that guidelines recommend mechanical valve replacement for patients younger than 50 years and indicate it may be considered for those aged 50 to 65 years.
    • In PARTNER 3, surgeons selected the surgical bioprosthetic valve they judged most likely to achieve optimal patient-specific hemodynamic, clinical, and durability outcomes.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        PARTNER 3 included low-risk patients; none were younger than 50 years, and 9.5% were aged 50 to 65 years.

        The surgical arm reflected contemporary standard-of-care practice during enrollment, with surgeons choosing among available bioprosthetic valves. Mechanical valve replacement was largely infeasible in this trial population.

        Clinical Best Practices

        • The authors describe all-cause BVF as encompassing reintervention, valve-related death, and irreversible severe bioprosthetic valve dysfunction.
        • The authors state that surgical bioprosthetic valves do not demonstrate a uniform class effect and that their durability is not equivalent.
        • The authors describe selection among approved valve platforms according to patient clinical and anatomic characteristics and lifetime-management considerations.

        Related Resources & Content

        Original Source(s)

        Related Content